Sym023 (Anti-TIM-3) in Patients With Advanced Solid Tumor Malignancies or Lymphomas

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

May 24, 2018

Primary Completion Date

June 3, 2020

Study Completion Date

June 3, 2020

Conditions

Metastatic CancerSolid TumorLymphoma

Interventions

DRUG

Sym023

Sym023 is a recombinant, fully human antibody that binds TIM-3 and induces activation of immune cells.

Trial Locations (4)

South Texas Accelerated Research Therapeutics (START) Midwest, Grand Rapids

The University of Texas MD Anderson Cancer Center, Houston

NEXT Oncology, San Antonio

Princess Margaret Cancer Centre, Toronto

All Listed Sponsors

lead

Symphogen A/S

INDUSTRY

NCT03489343 - Sym023 (Anti-TIM-3) in Patients With Advanced Solid Tumor Malignancies or Lymphomas | Biotech Hunter | Biotech Hunter